Survival of pancreatic cancer cells lacking KRAS function

Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. H...

Full description

Bibliographic Details
Main Authors: Noll, Elisa M. (Author), Sprick, Martin R. (Author), Trumpp, Andreas (Author), Muzumdar, Mandar (Contributor), Chen, Pan-Yu (Contributor), Dorans, Kimberly (Contributor), Chung, Katherine Minjee (Contributor), Bhutkar, Arjun (Contributor), Hong, Erin (Contributor), Jacks, Tyler E. (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Nature Publishing Group, 2017-12-11T19:48:01Z.
Subjects:
Online Access:Get fulltext